

Diseases, Complications, and Drug Therapy in Obstetrics



*A Guide
for
Clinicians*

Editors

**Gerald G. Briggs, BPharm,
FCCP**

Pharmacist Clinical Specialist
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical
Center
Long Beach, California
Clinical Professor of Pharmacy
University of California,
San Francisco
Adjunct Professor of Pharmacy
Practice
University of Southern California,
Los Angeles

Michael P. Nageotte, MD

Perinatologist
Associate Chief Medical Officer
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical
Center
Long Beach, California
Professor
Department of Obstetrics /
Gynecology
University of California, Irvine

American Society of Health-System Pharmacists®

Bethesda, Maryland

Any correspondence regarding this publication should be sent to the publisher, American Society of Health-System Pharmacists, 7272 Wisconsin Avenue, Bethesda, MD 20814, attention: Special Publishing.

The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product.

Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors, contributors, and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors, contributors, advisors, and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.

Director, Special Publishing: Jack Bruggeman

Acquisitions Editor: Rebecca Olson

Senior Editorial Project Manager: Dana Battaglia

Production Editor: Melissa Jones, Silverchair Science + Communications, Inc.

Page Design: David Wade

Cover Design: DeVall Advertising

Composition: Silverchair Science + Communications, Inc.

Library of Congress Cataloging-in-Publication Data

Diseases, complications, and drug therapy in obstetrics : a guide for clinicians / editors, Gerald G. Briggs, Michael P. Nageotte.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-58528-202-9

1. Obstetrical pharmacology. I. Briggs, Gerald G. II. Nageotte, Michael P. III. American Society of Health-System Pharmacists.

[DNLM: 1. Pregnancy Complications--drug therapy. 2. Embryo, Mammalian--drug effects. 3. Fetus--drug effects. 4. Lactation--drug effects. 5. Pregnancy--drug effects. WQ 240 D6116 2009]

RG528.D57 2009

618.3--dc22

2009015782

©2009, American Society of Health-System Pharmacists, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without written permission from the American Society of Health-System Pharmacists.

ASHP is a service mark of the American Society of Health-System Pharmacists, Inc.; registered in the U.S. Patent and Trademark Office.

ISBN: 978-1-58528-202-9

Foreword

William E. Smith, PharmD, MPH, PhD, FASHP
Executive Associate Dean, Professor of Pharmacy
School of Pharmacy, Virginia Commonwealth University
Medical College of Virginia Campus, Richmond, Virginia

This book is the result of many years of collaboration between pharmacists, physicians, and nurses in the care of obstetric patients and drugs affecting the fetus and newborn. Pharmacists in the clinical care of pregnant obstetric patients started at a few medical centers in the late 1960s and early 1970s. Today, with the possible exception of pharmacist services in labor/delivery, the pharmacy profession still has little involvement with pregnant patients, especially in the pharmacotherapeutic care of pregnant women with chronic disease and infections. There is an unmet demand for pharmacy services in the care of these patients. Moreover, there are numerous opportunities to work with maternal-fetal medicine physicians (a subspecialty of obstetrics that cares for high-risk pregnancies) in clinical research involving the drug therapy of pregnant or breastfeeding women.

The text provides an organized compilation of subject matter that can be used in the teaching of obstetric pharmacotherapy to pharmacy students and pharmacists. Knowledge of the physiology and diseases/complications unique to pregnancy is a prerequisite to understanding why drug therapy for the pregnant patient is markedly different from that of the nonpregnant patient. The arrangement of the book provides a good first step toward that knowledge and understanding. It also raises an important question to pharmacy educators and practitioners: What services are needed to increase the protection of the pregnant patient and fetus in acute, ambulatory, and community-based pharmacy services? Hopefully, the answer to the question will catalyze the teaching of medication use in pregnant patients and newborns in the curricula of pharmacy schools and will spur the interest of pharmacist practitioners. If this occurs, significant changes in the types and quantity of pharmacist clinical services for pregnant patients and newborns in acute and ambulatory care settings can occur.

An important feature of this text is the interprofessional relationship that has developed over the years between the editors. Gerald Briggs has been consistent and persistent in his pursuit over three decades to improve the quality of drug use in the pregnant patient to protect the fetus and newborn. He has provided clinical care to these patients, developed drug therapy guidelines, conducted research, published, and freely given his time to teach physicians, nurses, pharmacists, residents, and students.

Dr. Michael Nageotte, a superb maternal-fetal medicine physician, has assembled a highly proficient group of maternal fetal medicine physicians, labor and delivery nurses, clinical pharmacists, and other health professionals. Under his leadership, the combined efforts of this group consistently achieve extraordinary outcomes in complicated pregnancies. Their well-earned reputation has made the MemorialCare Center for Women at Long Beach Memorial Medical Center a major referral hospital for high-risk pregnancies.

The book also reflects the relationships that have developed over the years between the editors and contributors. Many of the contributors are recognized leaders in their fields. From their knowledge and clinical experience, the quality and safety of patient care have increased significantly. Their efforts to prepare and publish this textbook will benefit the care received by many more obstetric patients and newborns in the future.

Foreword

Roger K. Freeman, MD

Associate Medical Director for Women's Services

MemorialCare Center for Women

Miller Children's Hospital

Long Beach Memorial Medical Center

Long Beach, California

Clinical Professor of Obstetrics and Gynecology

University of California, Irvine

Those who participate in the obstetric care of a pregnant patient are challenged with making sure that their actions are beneficial to the mother and fetus-newborn. The use of drugs in the pregnant patient may be directed at the mother, fetus, or both. Only in pregnancy and lactation can a drug administered to one patient have a direct beneficial or detrimental effect on another being. It is for this reason that practitioners involved with pregnant and/or lactating patients must be constantly vigilant when using drugs.

Certainly there are instances in which a drug may be beneficial to both mother and fetus either directly or indirectly (eg, anti-infectives, anticonvulsants). In other circumstances a drug administered to the mother may have untoward effects on the fetus (eg, cancer chemotherapy), and drugs administered for the benefit of the fetus may have detrimental effects on the mother (eg, digoxin for treatment of fetal supraventricular tachycardia). These strategies must be undertaken with consideration for the risks. However, there are inevitably going to be instances in which there are currently unknown effects that may be detrimental to mother or fetus when treatment is directed at one or the other.

This text is aimed at educating obstetric caregivers, including physicians, pharmacists, and nurses, in the use of drugs in pregnancy. However, an equally important goal is to increase awareness of over-the-counter drugs to which patients have access. The use of such drugs is frequently unknown by the practitioner, which increases the need for obstetric caregivers to inquire about a patient's self-administered substances, both legal and illegal.

In recent years, clinical pharmacists have become increasingly pro-active in counseling patients about the drugs prescribed for them, as well as inquiring about other drugs a patient may be taking. At our hospital, clinical pharmacists are always present

on maternal-fetal medicine patient care rounds, and they have become much more involved in monitoring and managing the drug therapy of pregnant women with complicated conditions. This responsibility includes both hospitalized patients and ambulatory care. It is because of this increased involvement that this text is focused on pharmacists, as well as physicians and nurses who comprise the team that maximizes both safety and efficacy when drugs are used in pregnancy.

Preface

The concept for this book emerged in 2005. In our collective memories, there has always been a close working relationship between physicians and nurses and pharmacists in the MemorialCare Center for Women at Long Beach Memorial Medical Center. This professional relationship has played a major role in helping to make Women's a premier center for the care of both routine and high-risk pregnancies. Thus, it is in our best interest to assist in the training of these health care professionals for the care of obstetric patients. All nurses receive some training in obstetrics during their academic years. This has made the transition of new nurses into obstetrics an easier task.

However, such is not the case with pharmacists. For pharmacists, the absence of any training in obstetrics during their 4 years of formal postgraduate education makes such a transition a daunting journey, which can take many months to years before an acceptable level of competence is reached. It is encouraging that a number of pharmacy students come to Women's every year for an introduction to obstetrics. Their time with us is brief, but the students' feelings of accomplishment are universal in that they leave with an initial understanding and appreciation of this discipline. It is rewarding to observe these students progress from just "learning the language of Obstetrics" to becoming fledgling clinicians. Provided with the right opportunity, many of these students will become clinical pharmacists who have the ability to make outstanding contributions in the care of pregnant and lactating women. This book is one step of assistance toward making that opportunity a reality.

We are grateful for the 32 contributors who captured the essence of their topics. They covered complex subjects in a way that is easily understood, in spite of the restrictions of space and time. Each of the chapters could be expanded to many times their current size if all of the available information was included. Their ability to condense and select pertinent information and to present it in a meaningful way that promotes understanding is, in our opinion, a major accomplishment. We sincerely appreciate what they have done and thank them for their efforts.

Gerald G. Briggs, BPharm, FCCP
Pharmacist Clinical Specialist
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California
Clinical Professor of Pharmacy
University of California, San Francisco
Adjunct Professor of Pharmacy Practice
University of Southern California, Los Angeles

Michael P. Nageotte, MD
Perinatologist
Associate Chief Medical Officer
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California
Professor
Department of Obstetrics/Gynecology
University of California, Irvine

Contents

Foreword	iii
<i>William E. Smith</i>	
Foreword	v
<i>Roger K. Freeman</i>	
Preface	vii
Contributors	xi
Reviewers	xvii
Introduction	xix
<i>Gerald G. Briggs and Michael P. Nageotte</i>	
 Section I. General Considerations in Pregnancy and Lactation	
1. Physiologic Changes in Pregnancy	3
<i>Michael P. Nageotte</i>	
2. Developmental Toxicity and Drugs	15
<i>Gerald G. Briggs</i>	
3. Drug Use and Lactation	35
<i>Philip O. Anderson</i>	
4. Clinical Pharmacokinetics in the Pregnant Patient	55
<i>Carl W. Kildoo and Peter J. Ambrose</i>	
5. Use of Over-the-Counter Medications in Pregnancy	79
<i>Craig V. Towers</i>	
6. Teratology Risk Assessment and Counseling	99
<i>Dee Quinn</i>	
 Section II. Complications Unique to Pregnancy	
7. Preterm Labor and Delivery	123
<i>Annette E. Bombrys and David F. Lewis</i>	
8. Preterm Premature Rupture of Membranes	143
<i>Mounira Habli and David F. Lewis</i>	
9. Fetal Lung Maturity	155
<i>Kathleen M. Berkowitz</i>	
10. Multifetal Gestation	167
<i>John P. Elliott</i>	
11. Gestational Hypertension, Preeclampsia, and Eclampsia	177
<i>Julie Scott and Michael R. Foley</i>	

12. Abruptio Placentae.....	191
<i>Tamerou Asrat</i>	
13. Placenta Previa.....	205
<i>David Lagrew, Jr.</i>	
14. Fetal Arrhythmias.....	221
<i>Anjan S. Batra and John-Charles Loo</i>	
15. Induction of Labor.....	233
<i>Anna M. Galyean</i>	
16. Pain Control in Labor.....	243
<i>Michael Haydon</i>	
17. Postpartum Obstetric Hemorrhage.....	253
<i>Jennifer McNulty</i>	
Section III. Treatment of Chronic Diseases in Pregnancy	
18. Ambulatory Management of Asthma during Pregnancy.....	285
<i>Leslie Hendeles and Michael Schatz</i>	
19. Depression in Pregnancy.....	313
<i>Lisa O'Brien and Gideon Koren</i>	
20. Management of Gestational Diabetes.....	331
<i>Kathleen M. Berkowitz</i>	
21. Epilepsy in Pregnancy and Breastfeeding.....	347
<i>David L. Lourwood and Patricia R. Wigle</i>	
22. Chronic Hypertension in Pregnancy.....	367
<i>Kimey Ung and Elizabeth Yi</i>	
23. Infectious Disease.....	391
<i>Stephanie R. Chao</i>	
24. Nausea and Vomiting of Pregnancy.....	419
<i>Gerald G. Briggs and Michael P. Nageotte</i>	
25. Autoimmune Diseases in Pregnancy.....	433
<i>Eliza Chakravarty and Christina Chambers</i>	
26. Thromboembolic Disease in Pregnancy.....	455
<i>Wendy Abe Fukushima</i>	
27. Thyroid Disease in Pregnancy.....	479
<i>Julie J. Kelsey</i>	
Glossary.....	491
Index.....	501

Contributors

Peter J. Ambrose, PharmD, FASHP

Professor of Clinical Pharmacy
Vice Chair, Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco

Philip O. Anderson, PharmD, FASHP

Clinical Professor of Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of California, San Diego

Tamerou Asrat, MD

Director of Maternal Fetal Medicine
Hoag Memorial Hospital Presbyterian, Women's Pavilion
Newport Beach, California
Staff Perinatologist
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California
Clinical Associate Professor
Division of Maternal Fetal Medicine
Department of Obstetrics/Gynecology
University of California, Irvine

Anjan S. Batra, MD

Assistant Professor of Pediatrics
University of California, Irvine
Director of Electrophysiology
Children's Hospital of Orange County
Orange, California

Kathleen M. Berkowitz, MD

Regional Medical Director, Sweet Success Region 6.1
Clinical Associate Professor
Division of Maternal Fetal Medicine
Department of Obstetrics/Gynecology
University of California, Irvine

Annette E. Bombrys, DO

Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
University of Cincinnati
Cincinnati, Ohio

Gerald G. Briggs, BPharm, FCCP

Pharmacist Clinical Specialist
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California
Clinical Professor of Pharmacy
University of California, San Francisco
Adjunct Professor of Pharmacy Practice
University of Southern California, Los Angeles

Eliza Chakravarty, MD, MS

Assistant Professor of Medicine
Division of Immunology and Rheumatology
Stanford University School of Medicine
Palo Alto, California

Stephanie R. Chao, PharmD, BCPS, CDE

Senior Manager of Clinical Pharmacy
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Assistant Clinical Professor of Pharmacy
University of California, San Francisco

Christina Chambers, PhD, MPH

Associate Professor
Departments of Pediatrics, Family and Preventive Medicine
University of California, San Diego

John P. Elliott, MD

Director, Division of Maternal Fetal Medicine
Banner Good Samaritan Medical Center
Phoenix, Arizona
Clinical Professor
Department of Obstetrics/Gynecology
College of Medicine
University of Arizona, Tucson

Michael R. Foley, MD

Medical Director for Academic Affairs
Scottsdale Healthcare
Scottsdale, Arizona
Clinical Professor
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
College of Medicine
University of Arizona, Tucson

Wendy Abe Fukushima, PharmD, FCSHP

Women's Health Clinical Pharmacist
Hoag Memorial Hospital Presbyterian
Newport Beach, California

Anna M. Galyean, MD

Maternal Fetal Medicine
Magella Medical Group
Newport Beach, California

Mounira Habli, MD

Clinical Instructor
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
University of Cincinnati
Cincinnati, Ohio

Michael Haydon, MD

Assistant Clinical Professor
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
University of California, Irvine

Leslie Hendeles, PharmD

Professor
School of Pharmacy and Department of Pediatrics
University of Florida, Gainesville

Julie J. Kelsey, PharmD

Clinical Pharmacy Specialist, Women's Health
University of Virginia Health System
Department of Pharmacy Services
Charlottesville, Virginia

Carl W. Kildoo, PharmD

Director
Pharmacy Department
City of Hope
Duarte, California

Gideon Koren, MD, FRCPC, FACMT

Director, The Motherisk Program
The Hospital for Sick Children,
Professor of Pediatrics, Pharmacology, Pharmacy and Medical Genetics
The University of Toronto
Professor of Medicine, Pediatrics and Physiology/Pharmacology
and the Ivey Chair in Molecular Toxicology
The University of Western Ontario
Toronto, Ontario, Canada

David Lagrew, Jr., MD

Medical Director, Women's Hospital
Saddleback Memorial Medical Center
Laguna Hills, California
Clinical Professor
Division of Maternal Fetal Medicine
Department of Obstetrics/Gynecology
University of California, Irvine

David F. Lewis, MD, MBA

Professor and Vice-Chair
Fellowship Program Director
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
University of Cincinnati
Cincinnati, Ohio

John-Charles Loo, MD

Pediatric Cardiology
Southern California Permanente Medical Group
Bellflower, California
Volunteer Clinical Faculty
University of California, Irvine

David L. Lourwood, PharmD, BCPS, FCCP

Clinical Pharmacy Specialist
Department of Pharmacy Services
Popular Bluff Regional Medical Center
Adjunct Clinical Associate Professor of Pharmacy Practice
University of Missouri-Kansas City
Adjunct Clinical Assistant Professor of Pharmacy Practice
St. Louis College of Pharmacy
University of Arkansas for Medical Sciences

Jennifer McNulty, MD

Maternal Fetal Medicine
Magella Medical Group
Long Beach, California

Michael P. Nageotte, MD

Perinatologist
Associate Chief Medical Officer
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California
Professor
Department of Obstetrics/Gynecology
University of California, Irvine

Lisa O'Brien, MS, PhD(c)

Graduate Student
University of Toronto
Division of Clinical Pharmacology and Toxicology
The Hospital for Sick Children
Toronto, Ontario, Canada

Dee Quinn, MS, CGC

Director, Arizona Teratology Information Program
Executive Director, OTIS
College of Pharmacy
University of Arizona, Tucson

Michael Schatz, MD, MS

Chief, Allergy Department
Kaiser Permanente Medical Center
San Diego, California

Julie Scott, MD

Clinical Assistant
Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
College of Medicine
University of Arizona, Tucson

Craig V. Towers, MD

Maternal Fetal Medicine
Huntington Beach, California

Kimey Ung, PharmD, BCPS

Pharmacist Clinical Specialist
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California

Patricia R. Wigle, PharmD, BCPS

Assistant Professor
Clinical Pharmacy Practice
College of Pharmacy
University of Cincinnati
Cincinnati, Ohio

Elizabeth Yi, PharmD

Pharmacist Clinical Specialist
MemorialCare Center for Women
Miller Children's Hospital
Long Beach Memorial Medical Center
Long Beach, California

Reviewers

Kathryn J. Drennan, MD

Wayne State University
Detroit, Michigan

Lea S. Eiland, PharmD, BCPS

Auburn University Harrison School of Pharmacy
Huntsville, Alabama

Ruth A. Lawrence, MD, FABM, FAAP

Professor of Pediatrics and Obstetrics/Gynecology
Director of Breastfeeding and Human Lactation Study Center
University of Rochester School of Medicine
Rochester, New York

Donald R. Mattison, MD, CAPT, US Public Health Service

Senior Advisor to the Director of NICHD
Eunice Kennedy Shriver National Institute of Child Health and
Human Development
National Institutes of Health
Bethesda, Maryland

Edward J. Quilligan, MD

Professor Emeritus of Obstetrics and Gynecology
University of California, Irvine
Director of Medical Education
Long Beach Memorial/Miller Children's Hospital
Long Beach, California

Susan Scott Ricci, ARNP, MSN, MEd

University of Central Florida Nursing faculty
Orlando, Florida

Introduction

Gerald G. Briggs and Michael P. Nageotte

In 2006, approximately 4,300,000 babies were born in the United States and slightly over 350,000 in Canada. Although the majority of the births resulted in full-term, normal, healthy newborns, a significant number were premature or involved infants with structural birth defects. Additionally, a significant number of pregnancies had major complications or ended in abortions, either spontaneous or elective. Thus, although it is easy to overlook, pregnancy is a condition that can result in both good and poor outcomes.

Regardless of the eventual outcome, drug therapy is very common in pregnancy. There are many complications that are unique to pregnancy, and nearly all are treated with drugs. Furthermore, there are many chronic diseases that predate pregnancy and require continued drug treatment during gestation. Appropriate drug therapy is usually beneficial for the mother and the developing infant, but it can adversely affect the pregnancy and the newborn, as well as the nursing infant if continued after delivery. In order to obtain optimal pregnancy outcomes, the treatment of unique complications and chronic diseases requires clinicians with specific knowledge of obstetrics. Because drugs are used so commonly during pregnancy and lactation, pharmacists providing services to women of reproductive potential also require knowledge of obstetrics. Ideally, an introduction to obstetrics should be included in the pharmacy curriculum. The purpose of this book is to help meet that goal.

This book is primarily about drug therapy in pregnancy and, to a lesser extent, during lactation. It is critical to understand that treatment of the mother in either of these conditions potentially involves exposure of at least one other unintended patient: the embryo, fetus, or nursing infant. Clinicians must have access to references to estimate the risk of the therapy to these other "patients." The various chapters in this book will assist them in meeting this obligation. However, because the pharmacologic therapy of pregnant women is undergoing continuous change, no single source, including this book, will have all of the published reports or even cover all of the drugs. Thus, in addition to this book, we recommend a reference library that contains several other sources, such as those listed below (arranged alphabetically):

Books

- Briggs GG, Freeman RK, Yaffe SJ. *Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk*. 8th ed. Philadelphia: Lippincott, Williams & Wilkins, 2008.

- Hale T. *Medications and Mothers' Milk*. 13th ed. Amarillo, TX: Pharmasoft Medical Publishing, 2008.
- Koren G. *Medication Safety in Pregnancy and Breastfeeding*. New York: McGraw-Hill, 2007.
- Schaefer C, Peters P, Miller RK. *Drugs during Pregnancy and Lactation*. 2nd ed. London, UK: Academic Press, 2007.
- Schardein JL. *Chemically Induced Birth Defects*. 3rd ed. New York: Marcel Dekker, 2000.
- Shepard TH, Lemire RJ. *Catalog of Teratogenic Agents*. 12th ed. Baltimore: The Johns Hopkins University Press, 2007.

Online or Telephone

- LactMed, an online service of the National Library of Medicine. Available at: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT>.
- Organization of Teratology Information Specialists (OTIS). Available at: <http://otispregnancy.org> (free counseling on exposures during pregnancy and lactation for patients and healthcare professionals; toll free 866-626-OTIS).
- REPRORISK system: A commercially-available CD-ROM that contains electronic versions of REPROTEXT, REPROTOX, Shepard's Catalog, and TERIS. The system is available from <http://www.micromedex.com/products/reprorisk>.

There are three sections in this book: General Considerations in Pregnancy and Lactation, Complications Unique to Pregnancy, and Treatment of Chronic Diseases in Pregnancy.

The first section covers the physiological changes that occur in every pregnancy, as well as drug-induced developmental toxicity, drug exposure during breastfeeding, pregnancy-induced changes in pharmacokinetics, over-the-counter drugs in pregnancy, and risk communication. The focus of the latter chapter is on methods of communicating risks to patients so that it is done with current information and an understanding of counseling aspects. If risk communication is done properly, it can provide a significant measure of protection from medical liability for pharmacists working with pregnant patients.

Complications unique to pregnancy are covered in the second section. Preterm labor and delivery, fetal lung immaturity, gestational hypertension, preeclampsia and eclampsia, preterm rupture of the membranes, fetal cardiac arrhythmias, labor induction, fetal cardiac arrhythmias, and complications of the placenta are examples of complications that only occur in pregnancy. Also included is a chapter on how safe and effective pain control during child birth can be achieved. This is important because for many women child birth will be the most painful experience in their life. Additionally, there is a critical need to correctly recognize and treat postpartum hemorrhage. This condition has a high potential for maternal morbidity and mortality and is a leading cause of maternal death in the period immediately after delivery.

Section III addresses the treatment of chronic diseases and other disorders in pregnancy. The diseases and disorders covered are diabetes mellitus, infections, nausea and vomiting of pregnancy, chronic hypertension, depression, asthma, epilepsy, two

autoimmune disorders, thromboembolic disorders, and thyroid disease. Obviously, there are many more diseases that could have been discussed, but these are the most common in pregnancy. In each case, their treatment is complicated by the fact that at least one, and sometimes more, unintended patients are always present, the embryo(s) and/or fetus(es). Furthermore, the effects of a disease on the embryo-fetus are often much more severe than on the mother; diabetes mellitus is an excellent example. In other cases, there may be no proven benefit for the mother or the fetus from treatment, such as in mild chronic hypertension. In these situations, treatment may result only in risk. An understanding of the pregnant state, in addition to the disease pathology, is critical to achieving optimal pregnancy outcomes.

In addition to the editors, there are 32 contributors to the book. We have been very fortunate to obtain their assistance. We believe that their quick acceptance of our invitations to contribute was due to their recognition of the need for this book. All are clinicians and have special knowledge involving the treatment of pregnant women. Many are considered to be leading authorities on their subjects. In spite of their busy schedules, they have done very well in capturing the essence of their topics.

In our dual roles as editors and contributors, we hope this book will fulfill its purpose. If it does, we believe that pregnancy will be safer with improved outcomes for women everywhere.

